Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- CMIC HD Files NDA for UCD Treatment in Japan
February 22, 2012
- Shionogi, Eli Lilly Japan Announce Add’l Indication of DNP for Cymbalta
February 22, 2012
- IBL: ADAMTS5 Test Kit for Predicting Efficacy of Biologic Treatments in RA
February 22, 2012
- Glivec Receives Add’l Indication for HES/CEL: Novartis Pharma
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
- Kowa Launches Livalo in Mexico through Eli Lilly
February 21, 2012
- Sales of DPP-4 Inhibitors Reach ¥100 Billion Level, Antidiabetic Drugs Show Double-Digit Growth: IMS Japan
February 20, 2012
- Pfizer Japan Ranked No. 1 as Promotion Company: IMS Japan
February 20, 2012
- Qol President Nakamura Says “Proactive Cooperation” Needed for Distribution Improvement
February 20, 2012
- Daiichi Sankyo, Roche Announce Approval of Malignant Melanoma Treatment Vemurafenib in EU
February 20, 2012
- Diabetes Treatments: Their Development and Market
February 20, 2012
- With Upcoming Price Cuts, Nursing Homes Present Opportunity for Makers of Generic AD Treatments
February 20, 2012
- Fuso Acquires Exclusive Domestic Marketing Rights to Mucus Bulging Agent
February 20, 2012
- 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
- Qol Expects to Clear “30%” Generic Dispensing Mark Around October
February 17, 2012
- 40% of Doctors Prescribe Existing Drugs Until New Drug Information Is Clarified: Survey
February 17, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…